EP0039325A1 - Remede pour le traitement des infections virales de l'oeil et d'autres organes - Google Patents
Remede pour le traitement des infections virales de l'oeil et d'autres organesInfo
- Publication number
- EP0039325A1 EP0039325A1 EP79901504A EP79901504A EP0039325A1 EP 0039325 A1 EP0039325 A1 EP 0039325A1 EP 79901504 A EP79901504 A EP 79901504A EP 79901504 A EP79901504 A EP 79901504A EP 0039325 A1 EP0039325 A1 EP 0039325A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- viral
- viral infections
- eye
- organs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 15
- 230000009385 viral infection Effects 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- 210000000056 organ Anatomy 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 7
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 7
- 239000002671 adjuvant Substances 0.000 claims abstract description 3
- 239000003443 antiviral agent Substances 0.000 claims abstract description 3
- 230000003115 biocidal effect Effects 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 239000003981 vehicle Substances 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 102000014150 Interferons Human genes 0.000 abstract description 11
- 108010050904 Interferons Proteins 0.000 abstract description 11
- 229940079322 interferon Drugs 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 229940088598 enzyme Drugs 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 230000003612 virological effect Effects 0.000 abstract description 8
- 208000035143 Bacterial infection Diseases 0.000 abstract description 7
- 230000001580 bacterial effect Effects 0.000 abstract description 7
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 7
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 2
- 229960002773 hyaluronidase Drugs 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 2
- 229940053050 neomycin sulfate Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- -1 aliphatic alcohols Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003226 decolorizating effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
- 229960003962 trifluridine Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the invention relates to an agent for the treatment of viral infections of the eye and other organs.
- Antiviral substances such as interferon have been used to treat viral infections of the eye (Emödi et al., 1974, Jordan, 1974). An improvement in the viral infections was generally achieved, but in many cases a recurrence of an acute viral infection could not be prevented.
- the aim of the invention is an agent for the treatment of viral infections of the eye and other organs, both for preventive treatment and for the treatment of acute infections, such as those e.g. can be caused by the herpes simplex virus or the adenovirus, which enables effective prophylactic treatment and rapid and very effective control of acute viral infections.
- the invention proposes an agent for the treatment of viral infections of the eye and other organs from antiviral substance, adjuvants and vehicle, which is characterized in that it also contains, if necessary in the form of a separate preparation, a known antibiotic or several known antibiotics.
- the agent of the invention enables effective and rapid control of viral infections. It has been found in the context of the invention that there is a very close connection between a bacterial infection and a viral disease, ie that a viral disease is always a bacterial infection or a viral disease is accompanied by such a bacterial infection.
- bacterial enzymes are present in the focus of the disease. These bacterial enzymes, such as hyaluronidase, impair or prevent the formation of antiviral interferon in the cell, which enables the virus to penetrate and spread.
- a bacterial infection can be determined in addition to a viral infection and thus the beginning of a viral disease using the following method:
- the method consists of staining a glucose aminoglycan substrate with toluidine blue (an orthochromatic color) and then decolourising it, thereby obtaining a halo (lightened area) at the reaction site between the substrate and the decomposing enzyme.
- glucosaminoglycan substrate e.g. Chondroitin sulfate
- hyaluronidic acid in concentrations of 0.001 °. to 0.11.
- control plates are prepared:
- PBS Phoshate Buffer Saline
- Microplates the Hank material with agarose and the substrate and in addition the standard enzymes hyaluronidase (auferg dertestes) (1 mg / ml or solutions according to a standard card, at one place on the plate.
- hyaluronidase erythyluronidase
- a filter paper such as a disc, e.g. the strip for de: or the usual disc for an antibiogram micro capillary tubes.
- a filter paper such as a disc, e.g. the strip for de: or the usual disc for an antibiogram micro capillary tubes.
- Components of the agent 1. For local treatment (drops or ointment),
- Antibiotics Gentamycin sulfate or
- antibiotics are used for ophthalmic treatment.
- the amounts used correspond to the usual, but still need to be effective (bak ⁇ terizide minimum effect). In general, the amounts used vary between 3 mcg / ml and 100 mcg / ml.
- Neomycin sulfate in particular supports the interferon and facilitates its penetration.
- Metals such as silver, copper, mercury and iodine.
- Zinc Oxide 0.5% in saline is given.
- N-acetylcysteine another form of the cysteine group, is also recommended as an interferon stabilizer.
- Human fibroblastic interferon for local application in a dosage of 1x10 ref units / ml 2 to 6x / day for at least 7 days. It is a saline solution of phosphate buffer (pH 7), which also contains a solution of human albumin (0.3%).
- Poly I C (polylysine-CA cellulose), dissolved in phosphate buffer (pH 7) in a dosage of 1000 mcg / ml, is stored in a cooling system, for local application 100 to 200 units / 0.1 cm 3 6 to Administered 8x / day for at least 7 days (total therapeutic dose of 5000 to 30000 mcg). A total therapeutic dose of 30 mcg / 70 kg body weight is administered for intravenous use (that is 4000 to 6000 units in 24 hours).
- the neutralizers listed above should be used a few minutes before the administration of Poly I: C in order to achieve depolarization of the tissue. This depolarization prepares the intrusion of interferon.
- N-Acetylcysteindextran 0.05 ml / drop.
- Steroids for local use 0.05% to 0.5% to 1%, 4x / day, for general use 5 to 50 mg / day.
- the method is required to detect the onset of a viral disease and to begin effective treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Le remede pour le traitement des infections virales de l'oeil et d'autres organes a partir de substance antivirale, d'adjuvants et vehicules, renferme en outre un ou plusieurs antibiotiques connus, le cas echeant dans une preparation separee. Les infections bacteriennes presentes a cote des infections virales, seront ainsi combattues grace a l'antibiotique, empechant ainsi la formation d'enzymes bacteriens, comme l'hyaluronidase, qui inhibent la formation d'interferon dans la cellule. La presence d'une infection bacterienne avant et/ou pendant une infection virale peut etre mise en evidence par la presence d'enzymes bacteriens avant et pendant la maladie virale.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/DE1979/000123 WO1981001102A1 (fr) | 1979-10-19 | 1979-10-19 | Remede pour le traitement des infections virales de l'oeil et d'autres organes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0039325A1 true EP0039325A1 (fr) | 1981-11-11 |
Family
ID=6699862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP79901504A Withdrawn EP0039325A1 (fr) | 1979-10-19 | 1979-10-19 | Remede pour le traitement des infections virales de l'oeil et d'autres organes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0039325A1 (fr) |
| DD (1) | DD147005A5 (fr) |
| IT (1) | IT1126570B (fr) |
| WO (1) | WO1981001102A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080032A3 (fr) * | 1981-11-20 | 1985-11-13 | Enzo Biochem, Inc. | Préparation pharmaceutique pour le traitement de lésions herpétiques |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1091245A (en) * | 1963-12-09 | 1967-11-15 | Pfizer & Co C | Method for inducing resistance to viral infections in an animal |
| GB1170929A (en) * | 1965-12-28 | 1969-11-19 | Glaxo Lab Ltd | Antirival Nucleic Acids. |
| BE758977A (fr) * | 1969-11-17 | 1971-05-17 | Glaxo Lab Ltd | Procede biochimique |
| FR2134292A1 (en) * | 1971-04-30 | 1972-12-08 | Inst Nat Sante Rech Med | Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine |
| BE847990A (fr) * | 1975-11-07 | 1977-05-04 | Methode veterinaire, | |
| FR2374042A1 (fr) * | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
| GB2016015B (en) * | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| EP0004770B1 (fr) * | 1978-04-11 | 1984-06-13 | Efamol Limited | Composition pharmaceutique et diététique comprenant des acides gamma-linoléniques |
-
1979
- 1979-10-19 WO PCT/DE1979/000123 patent/WO1981001102A1/fr unknown
- 1979-10-19 EP EP79901504A patent/EP0039325A1/fr not_active Withdrawn
- 1979-11-16 DD DD79216966A patent/DD147005A5/de unknown
- 1979-12-07 IT IT28000/79A patent/IT1126570B/it active
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8101102A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1126570B (it) | 1986-05-21 |
| WO1981001102A1 (fr) | 1981-04-30 |
| IT7928000A0 (it) | 1979-12-07 |
| DD147005A5 (de) | 1981-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4323567B4 (de) | Aucubin zur Behandlung einer Hepatitis-B-Virus-Infektion | |
| DE68920656T2 (de) | Verwendung vpn Adenosin-5'-phosphate in der Behandlung von Krebscachexia. | |
| DE3027105A1 (de) | Verfahren zur herstellung eines die proliferation und differenzierung menschlicher granulopoetischer stammzellen stimulierenden faktors | |
| DE2832204A1 (de) | Mittel zur behandlung von nervenerkrankungen, verfahren zu seiner herstellung und seine verwendung | |
| DE3110610A1 (de) | Chemokinesine und chemotaxine der leukozyten und des entzuendungsgewebes: natuerliche mediatoren zur selektiven reversiblen motilitaetsbeinflussung (chemokinesis) und chemische anlockung (chemotaxis) bei der ansammlung von leukozyten | |
| DE2024586C3 (fr) | ||
| EP0095682A2 (fr) | Procédé de préparation de produits régénérateurs de cellules et de tissus | |
| DE3019847A1 (de) | Verfahren zur herstellung von menschlichem interferon und es enthaltende mittel | |
| EP0602686A2 (fr) | Concentrés des lectines d'extraits de gui et compositions standardisées, stabilisées des lectines de gui correspondantes, procédé pour leur préparation, ainsi que médicaments les contenant et leur utilisation | |
| DE68903065T2 (de) | Aus gingko biloba extrahierter biologischer regulator, wirksam in verschiedenen pathologien. | |
| EP0039325A1 (fr) | Remede pour le traitement des infections virales de l'oeil et d'autres organes | |
| DE602004006024T2 (de) | Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose | |
| DE69119576T2 (de) | Verfahren zur Abtrennung, Identifizierung und Quantifizierung von Isoenzymen und Isoformen der alkalischen Phosphatase | |
| DE69918953T2 (de) | Zusammensetzung von oligosacchariden zur regulierung von apoptose | |
| DE2538573A1 (de) | Uridine und diese enthaltende pharmazeutische praeparate | |
| DE2605576C3 (de) | Verfahren zum Isolieren der Proteasen Papain,,Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und Iyophilisirten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
| EP0017867A2 (fr) | Préparation pharmaceutique stimulant la prolifération des cellules hépatiques et facteur de protection et de croissance du foie | |
| DE2234832C2 (de) | Proteinfreies Hormonkonzentrat von Säugetier-Nebenschilddrüsen, dessen Herstellung und dieses Hormonkonzentrat enthaltende pharmazeutische Präparate | |
| EP0280135B1 (fr) | Protéine C-inhibiteur (PCI) comme agent pharmaceutique et diagnostic, procédé de préparation d'un tel agent pharmaceutique ou diagnostic ainsi qu'un milieu contenant le PCI | |
| DE3141970C2 (fr) | ||
| EP1096947B1 (fr) | Medicament topique pour le traitement d'infections virales | |
| DE2806181C2 (de) | Polysaccharid, Verfahren zu dessen Herstellung und Arzneimittel, das dieses Polysaccharid enthält | |
| Gauri et al. | Einfluß von 5-Äthyl-2′-desoxyuridin (ÄDU) auf die Regeneration der experimentell geschädigten Cornea | |
| DE2602542A1 (de) | Verfahren zur quantitativen bestimmung von glucoamylase im menschlichen urin und in koerperfluessigkeiten | |
| DE3249215T1 (de) | Verfahren zur herstellung von humanem (gamma)-interferon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT CH DE FR GB LU NL SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19811210 |